12: The Truth About CBD & Cannabis with Dr. Jess Peatross

Master Your Health Podcast

After working in the hospital for 6 years, Dr. Jess Peatross decided to leave her job and pursue further education in Functional Medicine. Her passion for preventive care and her search to find more tools to help heal her patients drove her down this path of self improvement and furthering her education. Now, she has the power to give her patients the best of both worlds with her training in both western medicine as an MD as well as Functional Medicine.

During her Functional Medicine training, she really began to understand and research the medicinal power of CBD and cannabis. Today, we’re picking her brain on CBD, cannabis and how sift through the BS on the market.

In this episode you’ll learn:

• How Dr. Jess’ experience in internal medicine and as a hospitalist led her to dig deeper into finding the root causes of chronic disease
• About the process that prescription drugs and medical devices go through to get “approved”
• Why it’s important to question the motive behind medical studies
• What exactly CBD is
• About the many uses and benefits of using CBD as medicine
• How to find high quality CBD and pinpoint the right dose for you
• What “full spectrum” CBD means
• How to spot a good CBD
• Why topical CBD balms work to help decrease inflammation
• About the difference between CBD and cannabis
• The difference between CBD from hemp and from cannabis
• How THC with CBD can help to fight cancer
• How THC can affect developing brains in young adults
• How CBD can affect pregnant women/new mothers
• How medical marijuana has been linked to lower narcotic use and death in some studies
• What the endocannabinoid system is
• How micro-dosing psilocybin has been shown to help some with addiction

@dr.jess.peatross | Nourish Medical Center San Diego | Online Education with Dr. Jessica Peatross

Resources / Links:

• Bayer sold HIV-risky meds - Factor VIII concentrate - https://www.cbsnews.com/news/bayer-sold-hiv-risky-meds/
• Caught selling a blood-clotting product that stopped potentially fatal bleeding in hemophiliacs but was linked to the risk of HIV infection. New York Times reported that it sold millions of dollars worth of an older version of the medication in Latin America and Asia while marketing a newer, safer product in the United States and Europe: https://www.nytimes.com/2003/05/22/business/2-paths-of-bayer-drug-in-80-s-riskier-one-steered-overseas.html